255 related articles for article (PubMed ID: 25684370)
21. Cardiac LXRα protects against pathological cardiac hypertrophy and dysfunction by enhancing glucose uptake and utilization.
Cannon MV; Silljé HH; Sijbesma JW; Vreeswijk-Baudoin I; Ciapaite J; van der Sluis B; van Deursen J; Silva GJ; de Windt LJ; Gustafsson JÅ; van der Harst P; van Gilst WH; de Boer RA
EMBO Mol Med; 2015 Sep; 7(9):1229-43. PubMed ID: 26160456
[TBL] [Abstract][Full Text] [Related]
22. Celastrol-Induced Suppression of the MiR-21/ERK Signalling Pathway Attenuates Cardiac Fibrosis and Dysfunction.
Cheng M; Wu G; Song Y; Wang L; Tu L; Zhang L; Zhang C
Cell Physiol Biochem; 2016; 38(5):1928-38. PubMed ID: 27160852
[TBL] [Abstract][Full Text] [Related]
23. Shensongyangxin protects against pressure overload‑induced cardiac hypertrophy.
Shen DF; Wu QQ; Ni J; Deng W; Wei C; Jia ZH; Zhou H; Zhou MQ; Bian ZY; Tang QZ
Mol Med Rep; 2016 Jan; 13(1):980-8. PubMed ID: 26648261
[TBL] [Abstract][Full Text] [Related]
24. Gramine protects against pressure overload-induced pathological cardiac hypertrophy through Runx1-TGFBR1 signaling.
Xu L; Su Y; Yang X; Bai X; Wang Y; Zhuo C; Meng Z
Phytomedicine; 2023 Jun; 114():154779. PubMed ID: 37023527
[TBL] [Abstract][Full Text] [Related]
25. Nrf2 protects against maladaptive cardiac responses to hemodynamic stress.
Li J; Ichikawa T; Villacorta L; Janicki JS; Brower GL; Yamamoto M; Cui T
Arterioscler Thromb Vasc Biol; 2009 Nov; 29(11):1843-50. PubMed ID: 19592468
[TBL] [Abstract][Full Text] [Related]
26. Aspirin Reduces Cardiac Interstitial Fibrosis by Inhibiting Erk1/2-Serpine2 and P-Akt Signalling Pathways.
Li X; Wang G; QiLi M; Liang H; Li T; E X; Feng Y; Zhang Y; Liu X; Qian M; Xu B; Shen Z; Gitau SC; Zhao D; Shan H
Cell Physiol Biochem; 2018; 45(5):1955-1965. PubMed ID: 29518782
[TBL] [Abstract][Full Text] [Related]
27. The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.
Avouac J; Palumbo-Zerr K; Ruzehaji N; Tomcik M; Zerr P; Dees C; Distler A; Beyer C; Schneider H; Distler O; Schett G; Allanore Y; Distler JH
Arthritis Rheumatol; 2014 Nov; 66(11):3140-50. PubMed ID: 25155144
[TBL] [Abstract][Full Text] [Related]
28. Smad3 Signaling Promotes Fibrosis While Preserving Cardiac and Aortic Geometry in Obese Diabetic Mice.
Biernacka A; Cavalera M; Wang J; Russo I; Shinde A; Kong P; Gonzalez-Quesada C; Rai V; Dobaczewski M; Lee DW; Wang XF; Frangogiannis NG
Circ Heart Fail; 2015 Jul; 8(4):788-98. PubMed ID: 25985794
[TBL] [Abstract][Full Text] [Related]
29. Carabin protects against cardiac hypertrophy by blocking calcineurin, Ras, and Ca2+/calmodulin-dependent protein kinase II signaling.
Bisserier M; Berthouze-Duquesnes M; Breckler M; Tortosa F; Fazal L; de Régibus A; Laurent AC; Varin A; Lucas A; Branchereau M; Marck P; Schickel JN; Deloménie C; Cazorla O; Soulas-Sprauel P; Crozatier B; Morel E; Heymes C; Lezoualc'h F
Circulation; 2015 Jan; 131(4):390-400; discussion 400. PubMed ID: 25369805
[TBL] [Abstract][Full Text] [Related]
30. Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway.
Xiao H; Ma X; Feng W; Fu Y; Lu Z; Xu M; Shen Q; Zhu Y; Zhang Y
Cardiovasc Res; 2010 Aug; 87(3):504-13. PubMed ID: 20200042
[TBL] [Abstract][Full Text] [Related]
31. Activation of LXR attenuates collagen-induced arthritis via suppressing BLyS production.
Huang Y; Fu X; Lyu X; Xu Z; He Z; Zhang Y; Zeng Y; He F; Huang G
Clin Immunol; 2015 Dec; 161(2):339-47. PubMed ID: 26431776
[TBL] [Abstract][Full Text] [Related]
32. Apelin prevents cardiac fibroblast activation and collagen production through inhibition of sphingosine kinase 1.
Pchejetski D; Foussal C; Alfarano C; Lairez O; Calise D; Guilbeau-Frugier C; Schaak S; Seguelas MH; Wanecq E; Valet P; Parini A; Kunduzova O
Eur Heart J; 2012 Sep; 33(18):2360-9. PubMed ID: 22028387
[TBL] [Abstract][Full Text] [Related]
33. Sympathetic alpha(2)-adrenoceptors prevent cardiac hypertrophy and fibrosis in mice at baseline but not after chronic pressure overload.
Gilsbach R; Schneider J; Lother A; Schickinger S; Leemhuis J; Hein L
Cardiovasc Res; 2010 Jun; 86(3):432-42. PubMed ID: 20083574
[TBL] [Abstract][Full Text] [Related]
34. Activation of liver X receptors with T0901317 attenuates cardiac hypertrophy in vivo.
Kuipers I; Li J; Vreeswijk-Baudoin I; Koster J; van der Harst P; Silljé HH; Kuipers F; van Veldhuisen DJ; van Gilst WH; de Boer RA
Eur J Heart Fail; 2010 Oct; 12(10):1042-50. PubMed ID: 20587624
[TBL] [Abstract][Full Text] [Related]
35. Protective effects of endogenous adrenomedullin on cardiac hypertrophy, fibrosis, and renal damage.
Niu P; Shindo T; Iwata H; Iimuro S; Takeda N; Zhang Y; Ebihara A; Suematsu Y; Kangawa K; Hirata Y; Nagai R
Circulation; 2004 Apr; 109(14):1789-94. PubMed ID: 14967720
[TBL] [Abstract][Full Text] [Related]
36. NF-kappaB activation is required for adaptive cardiac hypertrophy.
Zelarayan L; Renger A; Noack C; Zafiriou MP; Gehrke C; van der Nagel R; Dietz R; de Windt L; Bergmann MW
Cardiovasc Res; 2009 Dec; 84(3):416-24. PubMed ID: 19620128
[TBL] [Abstract][Full Text] [Related]
37. Deletion of soluble epoxide hydrolase attenuates cardiac hypertrophy via down-regulation of cardiac fibroblasts-derived fibroblast growth factor-2.
Zhang H; Wang T; Zhang K; Liu Y; Huang F; Zhu X; Liu Y; Wang MH; Tang W; Wang J; Huang H
Crit Care Med; 2014 May; 42(5):e345-54. PubMed ID: 24448199
[TBL] [Abstract][Full Text] [Related]
38. Liver X Receptor activation delays chondrocyte hypertrophy during endochondral bone growth.
Sun MM; Beier F
Osteoarthritis Cartilage; 2014 Jul; 22(7):996-1006. PubMed ID: 24852699
[TBL] [Abstract][Full Text] [Related]
39. RIP2 deficiency attenuates cardiac hypertrophy, inflammation and fibrosis in pressure overload induced mice.
Zhao CH; Ma X; Guo HY; Li P; Liu HY
Biochem Biophys Res Commun; 2017 Nov; 493(2):1151-1158. PubMed ID: 28698147
[TBL] [Abstract][Full Text] [Related]
40. Eplerenone prevents adverse cardiac remodelling induced by pressure overload in atrial natriuretic peptide-null mice.
Franco V; Chen YF; Feng JA; Li P; Wang D; Hasan E; Oparil S; Perry GJ
Clin Exp Pharmacol Physiol; 2006 Sep; 33(9):773-9. PubMed ID: 16922805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
